Antidepressant-like and anxiolytic-like activity of a novel indoleamine derivative ADN -2013 in rodents

• Authors: Anna Wasik , Anna Partyka , Magdalena Jastrzębska-Więsek , Marcin Kołaczkowski , Anna Wesołowska
• Languages of publication: EN EO

Abstracts

EN

A novel indolamine derivative, ADN-2013, has been proved to possess a preclinical activity profile appropriate for the treatment of behavioral and psychological symptoms of dementia. Its antidepressant and anxiolytic properties have been examined in rat and mice models. The receptor mechanisms underlying the antidepressant properties of ADN-2013 have also been elucidated. ADN-2013 significantly shortened the immobility time measured in the forced swim test in mice and rats, producing an effect that was abolished by the dopamine D1-receptor antagonist SCH 23390 in rats. Moreover, ADN-2013 evoked anxiolytic-like activity in both “conditional” and “unconditional” anxiety-like paradigms in mice and rats. From these results, it is likely that direct antagonism toward serotonin 5-HT6 receptors and an indirect effect of dopamine, acting mostly via D1-like receptors, may be involved in the antidepressant action of ADN-2013. However, the partial agonist activity of ADN-2013 toward D2 receptors, observed in in vitro studies, might also contribute to this effect.

Keywords

EN

antidepressant; antipsychotic; anxiolytic; mice; rats; schizophrenia

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Publisher: ZOZ Ośrodek UMEA SHINODA-KURACEJO
• Journal: Medicina Internacia Revuo
• Year: 2017
• Volume: 28
• Issue: 108
• Pages: 152-162

Contributors

author

Anna Wasik

author

Anna Partyka

author

Magdalena Jastrzębska-Więsek

author

Marcin Kołaczkowski

author

Anna Wesołowska

References

• 1. Braga, R. J.; Reynolds, G. P.; Siris, S. G.; Psychiatry Res. 2013, 210 (1), 1–7.
• 2. Buckley, P. F.; Miller, B. J.; Lehrer, D. S.; Castle, D.; J. Schizophr. Bull. 2009, 35 (2), 383–402.
• 3. Achim, A. M.; Maziade, M.; Raymond, É.; Olivier, D.; Mérette, C.; Roy, M. A.; Schizophr. Bull. 2011, 37 (4), 811–821.
• 4. Mulholland, C.; Cooper, S.; Depress. Schizophr. APT 2000, 6 (6), 169–177.
• 5. Felmet, K.; Zisook, S.; Kasckow, J. W.; Clin. Schizophr. Relat. Psychoses 2011, 4 (4), 239–250.
• 6. Ekinci, O.; Ugurlu, G. K.; Albayrak, Y.; Arslan, M.; Caykoylu, A.; Compr. Psychiatry 2012, 53 (2), 195–200.
• 7. Chiappelli, J.; Kochunov, P.; DeRiso, K.; Thangavelu, K.; Sampath, H.; Muellerklein, F.; Nugent, K. L.; Postolache, T. T.; Carpenter, W. T.; Hong, L. E.; Schizophr. Res. 2014, 159 (1), 243–248.
• 8. Petrovic, M.; Hurt, C.; Collins, D.; Burns, A.; Camus, V.; Liperoti, R.; Marriott, A.; Nobili, F.; Robert, P.; Tsolaki, M.; Vellas, B.; Verhey, F.; Byrne, E.; J. Acta Clin. Belg. 2007, 62 (6), 426–432.
• 9. Carmichael, O.; Lockhart, S.; Brain Imaging Behav. Neurosci. 2012, No. November 2011, 289– 320.
• 10. Young, J. W.; Powell, S. B.; Geyer, M. A.; Neuropharmacology 2012, 62 (3), 1381–1390.
• 11. Leysen, J. E.; In Atypical Antipsychotics; Ellenbroek, B. A., Cools, A. R., Eds.; Birkhäuser Basel: Basel, 2000; pp 57–81.
• 12. Meltzer, H. Y.; Massey, B. W.; Curr. Opin. Pharmacol. 2011, 11 (1), 59–67.
• 13. Etievant, A.; Bétry, C.; Haddjeri, N.; Open Neuropsychopharmacol. J. 2010, 3, 1–12.
• 14. Kolaczkowski, M.; Marcinkowska, M.; Bucki, A.; Sniecikowska, J.; Pawlowski, M.; Kazek, G.; Siwek, A.; Jastrzebska-Wiesek, M.; Partyka, A.; Wasik, A.; Wesolowska, A.; Mierzejewski, P.; Bienkowski, P.; Eur. J. Med. Chem. 2015, 92, 221–235.
• 15. Porsolt, R. D.; Bertin, A.; Jalfre, M.; Arch. Int. Pharmacodyn. Ther. 1977, 229 (2), 327–336.
• 16. Porsolt, R. D.; Anton, G.; Blavet, N.; Jalfre, M.; Eur. J. Pharmacol. 1978, 47 (4), 379–391.
• 17. Vogel, J. R.; Beer, B.; Clody, D. E.; Psychopharmacologia 1971, 21 (1), 1–7.
• 18. Eddy, N. B.; Leimbach, D.; J. Pharmacol. Exp. Ther. 1953, 107 (3), 385–393.
• 19. Pellow, S.; File, S. E.; Pharmacol. Biochem. Behav. 1986, 24 (3), 525–529.
• 20. Broekkamp, C. L.; Rijk, H. W.; Joly-Gelouin, D.; Lloyd, K. L. Eur.; J. Pharmacol. 1986, 126 (3), 223–229.
• 21. Porsolt, R. D.; Biomedicine 1979, 30 (3), 139–140.
• 22. Wesołowska, A.; Nikiforuk, A.; Neuropharmacology 2007, 52 (5), 1274–1283.
• 23. Kolaczkowski, M.; Mierzejewski, P.; Bienkowski, P.; Wesolowska, A.; Newman-Tancredi, A.; Eur. Neuropsychopharmacol. 2017, 23, S536.
• 24. Hirst, W. D.; Stean, T. O.; Rogers, D. C.; Sunter, D.; Pugh, P.; Moss, S. F.; Bromidge, S. M.; Riley, G.; Smith, D. R.; Bartlett, S.; Heidbreder, C. A.; Atkins, A. R.; Lacroix, L. P.; Dawson, L. A.; Foley, A. G.; Regan, C. M.; Upton, N.; Eur. J. Pharmacol. 2006, 553 (1-3), 109–119.
• 25. Hirst, W. D.; Abrahamsen, B.; Blaney, F. E.; Calver, A. R.; Aloj, L.; Price, G. W.; Medhurst, A. D.; Mol. Pharmacol. 2003, 64 (6), 1295–1308.
• 26. Li, Z.; Huang, M.; Prus, A. J.; Dai, J.; Meltzer, H. Y.; Brain Res. 2007, 1134 (1), 70–78.
• 27. Dawson, L. A.; Nguyen, H. Q.; Li, P.; Brain Res. Bull. 2003, 59 (6), 513–521.
• 28. Frantz, K. J.; Hansson, K. J.; Stouffer, D. G.; Parsons, L. H.; Neuropharmacology 2002, 42 (2), 170–180.
• 29. Pullagurla, M.; Bondareva, T.; Young, R.; Glennon, R. A.; Pharmacol. Biochem. Behav. 2004, 78 (2), 263–268.
• 30. Wang, P.; Si, T.; Shanghai Archives of Psychiatry. June 2013, pp 134–140.
• 31. Millan, M. J.; Prog. Neurobiol. 2003, 70 (2), 83–244.
• 32. Vulink, N. C. C.; Figee, M.; Denys, D.; Eur. Neuropsychopharmacol. 2011, 21 (6), 429–449.
• 33. Rogoz, Z.; Skuza, G.; Pharmacol. Rep. 2011, 63 (6), 1547–1552.
• 34. Ratajczak, P.; Kus, K.; Giermaziak, W.; Nowakowska, E.; Pharmacol. Reports 2016, 68 (2), 415–422.
• 35. Bruins Slot, L. A.; Bardin, L.; Auclair, A. L.; Depoortere, R.; Newman-Tancredi, A.; Behav. Pharmacol. 2008, 19 (2), 145–152.
• 36. Wesolowska, A.; Nikiforuk, A.; Stachowicz, K.; Tatarczynska, E.; Neuropharmacology 2006, 51 (3), 578–586.
• 37. Wesołowska, A.; Nikiforuk, A.; Eur. J. Pharmacol. 2008, 582 (1-3), 88–93.
• 38. Hascoët, M.; Bourin, M.; Todd, K. G.; du Tertre, A. C.; J. Psychopharmacol. 1994, 8 (4), 227–237.
• 39. Pauwels, P.; Neuropharmacology 2003, No. 0927, 1–12.
• 40. Fulton, B.; Brogden, R. N.; CNS Drugs 1997, 7 (1), 68–88.
• 41. Jahromy, M. H.; Shariatifar, A.; Samiee, S.; Vaziri, M.; Shahraki, M. B.; Dara, S. M.; World J Neurosci. 2014, 4, 293–298.

• Document Type: article